Overview

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC